“Patient advocacy, disability, veterans, minority and provider groups are taking their place at the table and raising serious concerns about the negative impact of the FDA Proposed Rule on Generic Labeling,” said Ralph G. Neas, President and CEO of the Generic Pharmaceutical Association (GPhA.) “The number of voices is mounting; last week, we heard from more than 20 organizations across the healthcare supply chain. Now we are hearing from patient populations historically and currently underserved by our nation’s health care system. Read More